Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/24993
Başlık: A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction
Yazarlar: Ergin, Süreyya
Gündüz, Berrin
Uğurlu, Hatice
Öncel, Sema
Gök, Haydar
Erhan, Belgin
Levendoğlu, Funda
Senocak, Özlem
Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.
Sivrioǧlu, Konçuy
56245687600
Anahtar kelimeler: Neurosciences & neurology
Erectile dysfunction
Impotence
Paraplegia
Sildenafil
Spinal cord injuries
Tetraplegia
Quality-of-life
Citrate
Satisfaction
Viagra(r)
Yayın Tarihi: 2008
Yayıncı: Taylor & Francis
Atıf: Ergin, S. vd. (2008). ''A placebo-controlled, multicenter, randomized, double-blind, flexible- ver study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction''. Journal of Spinal Cord Medicine, 31(5), 522-531.
Özet: Background/Objective: To show the efficacy, safety, and tolerability of sildenafil in men with erectile dysfunction (ED) associated with complete or incomplete spinal cord injury (SCI) and to assess its effects on quality of life (QoL) using the Life-Satisfaction Check List. Methods: This was a placebo-controlled, multicenter, randomized, double-blind, flexible-dose, 2-way crossover study with a 2-week washout period between each phase. Patients with ED attributable to SCI (Sexual Health Inventory-Male score <= 21) received 50 to 100 mg sildenafil (n = 24) or placebo (n = 26). Results: Compared with placebo, sildenafil produced higher levels of successful sexual stimulation, intercourse success, satisfaction with sexual life and sexual relationship, erectile function, overall sexual satisfaction, and an improved Erectile Dysfunction Inventory of Treatment Satisfaction score, with no clinically relevant effects on vital signs. Sildenafil seemed more effective in patients with incomplete SCI than in those with complete SCI, producing significant improvements, compared with placebo, in a number of measures only in patients with incomplete SCI. All patients who expressed a preference selected sildenafil over placebo, although the drug had no effect on patient QoL. Sildenafil was well tolerated, with a profile comparable to that of placebo. Conclusions: Compared with placebo, treatment with oral sildenafil safely and effectively improved erectile function in patients with ED attributable to SCI, especially in those with incomplete injury, and was the agent of choice in those who expressed a preference.
URI: https://doi.org/10.1080/10790268.2008.11753647
https://www.tandfonline.com/doi/abs/10.1080/10790268.2008.11753647
http://hdl.handle.net/11452/24993
ISSN: 1079-0268
2045-7723
Koleksiyonlarda Görünür:PubMed
Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Sivrioğlu_vd_2008.pdf17.84 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons